Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings Tempus AI, Inc. a technology company leading the adoption of AI to advance precision medicine, announced the publication of a new study in JCO Precision…
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received…
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…
TIXiMED Reports Promising Preclinical Results for Oral TIX100 in Preventing Weight Regain After GLP-1 Therapy TIXiMED a clinical-stage pharmaceutical company focused on developing innovative treatments for diabetes and metabolic diseases, has announced encouraging new preclinical findings for its investigational oral…
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy Vertex Pharmaceuticals Incorporated today announced positive data from a pre-specified Week 36 interim…
Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis Pfizer Inc. today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its…
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for weight management and metabolic health, reinforces its position as a…
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to…
FUJIFILM Biotechnologies Unveils ShunzymeX™ Precision Purification Technology FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today unveils ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics. The technology will…
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and…
Roche’s fenebrutinib reaffirms potential as the sole BTK inhibitor for relapsing and primary progressive MS with positive FENhance 1 Phase III results. Roche announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary…
Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening Wisdom Bioscience, a biotechnology company revolutionizing oral cancer diagnostics, has announced the formation of its Scientific Advisory Board (SAB) following a successful initial funding round. The SAB…